While investors have been left underwhelmed by Eli Lilly’s 14% gain over the past year, a generics giant from Israel has quietly stolen the spotlight. Teva Pharmaceutical Industries (NYSE: TEVA) has more than doubled in value over the last 12 months, emerging as a dazzling performer in the healthcare sector.
The fireworks began on Jan. 28, when Teva released its fourth-quarter and full-year 2025 earnings. The numbers were eye-popping: Q4 revenue came in at $4.7 billion, up 11% year over year, while adjusted earnings per share of $0.96 blew past analyst forecasts of $0.64. For the full year, revenue grew 5%, and non-GAAP earnings jumped 19%. On the surface, this looks like a flawless report card.
But peel back the layers, and the picture becomes more nuanced. The results were juiced by a $500 million milestone payment from Sanofi related to duvakitug, their jointly developed candidate for ulcerative colitis and Crohn’s disease. Strip out that one-time windfall, and Teva’s revenue and earnings would have risen by only a few percentage points compared to 2024. More concerning, management’s guidance for 2026 calls for an overall revenue decline, dubbing it a “transition year.”
Despite the near-term revenue pressure, long-term investors see a company in the midst of a difficult but necessary pivot from generics to innovative specialty drugs. Currently, branded products like Austedo (for Huntington’s disease chorea), Ajovy (migraine), and Uzedy (a long-acting injection for schizophrenia) are growing strongly enough to offset the sluggishness in the generics segment. Management’s goal is for these products to command a growing share of the revenue mix, eventually driving margin expansion and accelerating earnings growth.
Then there’s the pipeline. Teva projects that duvakitug alone could reach peak annual sales of $2 billion to $5 billion. Add in other candidates, and the pipeline’s total peak sales potential exceeds $10 billion. While analysts expect EPS to dip 8.5% in 2026, they forecast a rebound of 12.3% in 2027. Based on 2026 earnings estimates, Teva trades at just 12.5 times forward earnings—somewhere in the middle to lower end of the pharmaceutical sector’s valuation range. If growth accelerates in 2027, the stock could benefit from both earnings growth and multiple expansion. Bulls argue it’s not too late to get in, and any unexpected pullback would represent a screaming buying opportunity.
Conservative investors, however, aren’t buying the story. Their concerns break down into three main arguments.
First, the generics business itself is getting harder. Competition has intensified over the years, squeezing margins. While Teva is pivoting toward complex generics to build a moat, that strategy requires higher R&D investment and carries greater risk of failure.
Second, Teva is now betting on innovative drug development, putting it in direct competition with deep-pocketed giants like Pfizer and Merck that have decades of R&D expertise and commercial firepower. Even these titans stumble. Pfizer, for instance, recently abandoned its internally developed GLP-1 candidate and had to quickly fill the gap through acquisitions and partnerships. Does Teva have the financial flexibility and strategic agility to pivot like that if its own pipeline underperforms? That remains an open question.
Third, the stock’s recent run may have already priced in much of the transformation story. As one self-described conservative analyst put it: “I can see why some investors like Teva’s story. But the risks inherent in this business model shift, in such a competitive sector, are more than I want to take on. Maybe after the new strategy has a longer track record, I’ll reconsider.”
The bull and bear cases aren’t mutually exclusive; they reflect different time horizons and risk tolerances. Short-term traders may continue to ride the earnings momentum, but fundamental investors need to answer one core question: Can Teva successfully navigate the “valley of death” between generics and innovation?
At 12.5 times forward earnings, the valuation isn’t demanding. But the market is already bracing for a revenue decline in 2026. The real test is whether 2027 and beyond can deliver the growth management has promised. Sanofi’s milestone payment suggests external validation of duvakitug’s potential, but whether a single drug candidate can support a multi-billion-dollar valuation remains to be seen.
For long-term investors willing to tolerate volatility and bet on a turnaround, Teva’s current price offers a way to play the pipeline story. For risk-averse investors who prioritize stable cash flows and certainty, Teva’s narrative may still lack the necessary proof points. The earnings were explosive. The stock has soared. But whether Teva is worth buying ultimately comes down to whether you believe in the transformation story—or fear the risks still lurking beneath the surface. For now, only time will deliver the final answer.
